2 results
Approved WMOCompleted
The objectives of this study are to compare the safety and efficacy of 2 annual cycles of intravenous (IV) alemtuzumab to 3-times weekly subcutaneous (SC) interferon beta 1a (Rebif*) in patients with active relapsing-remitting multiple sclerosis (…
Approved WMOCompleted
The primary aim of the study is to compare the effect of PRO symptom monitoring with standard care on QoL both during and up to 1 year after treatment. Secondary aims are studying the effect of PRO symptom monitoring compared to standard care on the…